Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 10 2024
22 10 2024
Historique:
received:
15
04
2024
accepted:
08
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
22
10
2024
Statut:
epublish
Résumé
Multiple sclerosis is an inflammatory demyelinating disease and represents a global health concern. Ocrelizumab, a humanized IgG monoclonal antibody, selectively targets CD20 on B cells and CD20-expressing T cells. This study aimed to compare the efficacy and safety of the biosimilar ocrelizumab candidate (Xacrel) to the originator product (Ocrevus) in Relapsing Multiple Sclerosis (RMS) patients. In this randomized trial, patients received either Xacrel or Ocrevus for 96 weeks. The primary endpoint was the equivalency of the medications in reducing the annualized relapse rate (ARR) at week 48. The secondary endpoints included time to the onset of disability progression confirmed at 12 and 24 weeks, the proportion of relapse-free patients, magnetic resonance imaging (MRI) evaluations, safety assessments, and immunogenicity over 96 weeks. A total of 170 patients were randomized (1:1 ratio). In the per protocol analysis, the upper and lower limits of 95% two-sided confidence intervals of difference between treatments in the 48-week ARR rate were in the predefined margin of - 0.2 to 0.2 (- 0.002; 95% CI - 0.080 to 0.075). The two products were also comparable in terms of other efficacy parameters, safety, and immunogenicity. The results confirmed that Xacrel is equivalent to Ocrevus in terms of 48-week ARR in RMS patients, with no considerable difference in other efficacy parameters and the safety profile during the 96 weeks. The trial was registered in Iranian registry of clinical trials (IRCT) on 10/06/2019 with the registration number of IRCT20150303021315N13 and in Clinicaltrials.gov on 19/07/2021 with the registration code of NCT04966338.
Identifiants
pubmed: 39438591
doi: 10.1038/s41598-024-75745-y
pii: 10.1038/s41598-024-75745-y
doi:
Substances chimiques
ocrelizumab
A10SJL62JY
Antibodies, Monoclonal, Humanized
0
Biosimilar Pharmaceuticals
0
Banques de données
ClinicalTrials.gov
['NCT04966338']
Types de publication
Journal Article
Randomized Controlled Trial
Clinical Trial, Phase III
Multicenter Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
24921Subventions
Organisme : CinnaGen
ID : 701.967
Informations de copyright
© 2024. The Author(s).
Références
Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 26, 1816–1821. https://doi.org/10.1177/1352458520970841 (2020).
doi: 10.1177/1352458520970841
pubmed: 33174475
pmcid: 7720355
Mirmosayyeb, O., Shaygannejad, V., Bagherieh, S., Hosseinabadi, A. M. & Ghajarzadeh, M. Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis. Neurol. Sci. 43, 233–241. https://doi.org/10.1007/s10072-021-05750-w (2022).
doi: 10.1007/s10072-021-05750-w
pubmed: 34787755
Hauser, S. L. & Cree, B. A. C. Treatment of multiple sclerosis: a review. Am. J. Med. 133, 1380–1390e1382. https://doi.org/10.1016/j.amjmed.2020.05.049 (2020).
doi: 10.1016/j.amjmed.2020.05.049
pubmed: 32682869
pmcid: 7704606
Ford, H. Clinical presentation and diagnosis of multiple sclerosis. Clin. Med. (Lond). 20, 380–383. https://doi.org/10.7861/clinmed.2020-0292 (2020).
doi: 10.7861/clinmed.2020-0292
pubmed: 32675142
Vucic, S., Burke, D. & Kiernan, M. C. Fatigue in multiple sclerosis: mechanisms and management. Clin. Neurophysiol. 121, 809–817. https://doi.org/10.1016/j.clinph.2009.12.013 (2010).
doi: 10.1016/j.clinph.2009.12.013
pubmed: 20100665
Ciotti, J. R. & Cross, A. H. Disease-Modifying treatment in progressive multiple sclerosis. Curr. Treat. Options Neurol. 20 https://doi.org/10.1007/s11940-018-0496-3 (2018).
Simpson, A., Mowry, E. M. & Newsome, S. D. Early aggressive treatment approaches for multiple sclerosis. Curr. Treat. Options Neurol. 23, 19. https://doi.org/10.1007/s11940-021-00677-1 (2021).
doi: 10.1007/s11940-021-00677-1
pubmed: 34025110
pmcid: 8121641
D’Amico, E. et al. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun. Rev. 18, 665–672. https://doi.org/10.1016/j.autrev.2019.05.003 (2019).
doi: 10.1016/j.autrev.2019.05.003
pubmed: 31059839
Michel, L. et al. B cells in the multiple sclerosis Central Nervous System: trafficking and contribution to CNS-Compartmentalized inflammation. Front. Immunol. 6, 636. https://doi.org/10.3389/fimmu.2015.00636 (2015).
doi: 10.3389/fimmu.2015.00636
pubmed: 26732544
pmcid: 4689808
Mulero, P., Midaglia, L. & Montalban, X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther. Adv. Neurol. Disord. 11, 1756286418773025. https://doi.org/10.1177/1756286418773025 (2018).
doi: 10.1177/1756286418773025
pubmed: 29774057
pmcid: 5952271
Shinoda, K. et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proc. Natl. Acad. Sci. U S A. 120, e2207291120. https://doi.org/10.1073/pnas.2207291120 (2023).
doi: 10.1073/pnas.2207291120
pubmed: 36634138
pmcid: 9934304
Hauser, S. L. et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl. J. Med. 376, 221–234. https://doi.org/10.1056/NEJMoa1601277 (2017).
doi: 10.1056/NEJMoa1601277
pubmed: 28002679
Greenberg, B. & Giovannoni, G. A place for biosimilars in the changing multiple sclerosis treatment landscape. Mult Scler. Relat. Disord. 77, 104841. https://doi.org/10.1016/j.msard.2023.104841 (2023).
doi: 10.1016/j.msard.2023.104841
pubmed: 37467536
Global Regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the global burden of Disease Study 2021. Lancet Neurol. 23, 344–381. https://doi.org/10.1016/s1474-4422(24)00038-3 (2024).
doi: 10.1016/s1474-4422(24)00038-3
Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of Anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112, 90–92. https://doi.org/10.1016/j.ad.2019.05.009 (2021).
doi: 10.1016/j.ad.2019.05.009
pubmed: 32891586
Blackwelder, W. C. Equivalence Trials. In Encyclopedia of Biostatistics, vol. 21367–1372 (Wiley, 1998).
Team, R. C. R: A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing. https://www.r-project.org/ (2020).
Hauser, S. L. et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 95, e1854–e1867. https://doi.org/10.1212/wnl.0000000000010376 (2020).
doi: 10.1212/wnl.0000000000010376
pubmed: 32690791
pmcid: 7682822
Pontieri, L. et al. Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study. Eur. J. Neurol. 29, 496–504. https://doi.org/10.1111/ene.15142 (2022).
doi: 10.1111/ene.15142
pubmed: 34644452
Fernandez-Diaz, E. et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann. Clin. Transl Neurol. 8, 385–394. https://doi.org/10.1002/acn3.51282 (2021).
doi: 10.1002/acn3.51282
pubmed: 33369288
Ellwardt, E. et al. Ocrelizumab initiation in patients with MS: a multicenter observational study. Neurol. Neuroimmunol. Neuroinflamm. 7. https://doi.org/10.1212/nxi.0000000000000719 (2020).
Weinstock-Guttman, B. et al. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: a nonrandomized controlled trial. Mult Scler. 28, 790–800. https://doi.org/10.1177/13524585211035740 (2022).
doi: 10.1177/13524585211035740
pubmed: 34382875
Garcia-Cañibano, B. et al. Real-world experience of ocrelizumab in multiple sclerosis in an arab population. J. Drug Assess. 10, 106–113. https://doi.org/10.1080/21556660.2021.1989193 (2021).
doi: 10.1080/21556660.2021.1989193
pubmed: 34692185
pmcid: 8530478